What is the appropriate initial evaluation and pharmacologic management for a patient with heart failure, including assessment of ejection fraction and guideline‑directed therapy?

Heart Failure: Initial Evaluation and Pharmacologic Management

All patients with suspected heart failure require transthoracic echocardiography (TTE) to assess left ventricular ejection fraction (LVEF), as this single measurement determines the entire treatment algorithm and prognosis 1.

Initial Evaluation

Essential Diagnostic Steps

• Obtain TTE immediately to measure LVEF and assess myocardial structure/function—this is the cornerstone that classifies patients into HFrEF (LVEF ≤40%), HFmrEF (LVEF 41-49%), or HFpEF (LVEF ≥50%) 1

• Measure natriuretic peptides (BNP or NT-proBNP) for diagnostic confirmation, particularly useful as a "rule-out" test due to high negative predictive value 2

• Assess filling pressures in patients with LVEF >40% through either:

  • Noninvasive: natriuretic peptides, diastolic function on imaging
  • Invasive: hemodynamic measurements 3

• Identify precipitating factors: ischemic heart disease (most common cause), hypertension, valvular disease, arrhythmias 2, 4

• Check baseline labs: renal function (creatinine, eGFR), electrolytes (potassium, sodium), and avoid NSAIDs which worsen outcomes 2

Pharmacologic Management for HFrEF (LVEF ≤40%)

Quadruple Therapy: The New Standard

Initiate all four medication classes simultaneously or in rapid sequence within 6-12 weeks of diagnosis to reduce mortality and hospitalizations 5, 6, 3, 7:

1. ACE Inhibitor (or ARB if ACE-I not tolerated, or ARNI)

   • Start low dose, titrate to target doses proven in trials
   • Monitor BP, renal function, and electrolytes at 1-2 weeks after each dose increase, then at 3 months, then every 6 months 2
   • Critical: Reduce or withhold diuretics for 24 hours before initiating to prevent hypotension 2
   • Avoid potassium-sparing diuretics during initiation 2

2. Beta-Blocker (carvedilol, metoprolol succinate, or bisoprolol)

   • Recommended for all stable HFrEF patients (NYHA II-IV) to reduce mortality 2, 1
   • Start after patient is stabilized on ACE-I and diuretics
   • Level A evidence for mortality reduction 2

3. Mineralocorticoid Receptor Antagonist (MRA)

   • Add for patients remaining symptomatic despite ACE-I and beta-blocker 1
   • Spironolactone reduces mortality in NYHA III-IV (Level B evidence) 2
   • Monitor potassium and creatinine closely: check at 5-7 days, recheck every 5-7 days until stable 2

4. SGLT2 Inhibitor (dapagliflozin or empagliflozin)

   • This is the newest addition to guideline-directed medical therapy 5, 6, 3
   • Class 2a recommendation with meaningful mortality reduction
   • Can be initiated regardless of diabetes status 5, 6, 3, 7

Upgrade to Sacubitril/Valsartan (ARNI)

Replace ACE-I with sacubitril/valsartan in ambulatory patients who remain symptomatic despite optimal triple therapy (ACE-I, beta-blocker, MRA) to further reduce HF hospitalization and death (Class I, Level B) 1.

Diuretics for Congestion

• Loop diuretics or thiazides for symptomatic relief when fluid overload is present 2, 1
• Always administer with ACE-I 2
• If GFR <30 mL/min, avoid thiazides except synergistically with loop diuretics 2
• For insufficient response: increase dose, combine loop diuretics with thiazides, or add metolazone in severe cases with frequent creatinine/electrolyte monitoring 2

Secondary Therapies (For Persistent Symptoms)

• Digoxin: For atrial fibrillation with any degree of HF to control ventricular rate (Level B), or for persistent symptoms in sinus rhythm despite optimal therapy (Level B) 2

  • Dose: 0.25-0.375 mg daily (0.125-0.25 mg in elderly)
  • Target serum concentration ≤1.0 ng/dL 4

• Hydralazine + Isosorbide Dinitrate: If ACE-I/ARB not tolerated 7, 4

• Ivabradine or Vericiguat: For select patients with worsening symptoms 7

Management for HFmrEF (LVEF 41-49%)

• SGLT2i: Class 2a recommendation 5, 3
• Weaker recommendations (Class 2b) for ARNI, ACE-I, ARB, MRA, and beta-blockers 5, 3

Management for HFpEF (LVEF ≥50%)

The evidence base is weaker but expanding:

• SGLT2i: Class 2a recommendation—strongest evidence for reducing HF hospitalizations 5, 3, 8, 9
• MRA: Class 2b recommendation 5, 3
• ARNI: Class 2b recommendation 5, 3
• Aggressive treatment of hypertension: Class I recommendation 1
• Manage atrial fibrillation: Class 2a recommendation 5, 3
• ARBs: Class 2b recommendation 5, 3
• Avoid routine nitrates or phosphodiesterase-5 inhibitors: Class III (No Benefit) 5, 3

Critical Monitoring Parameters

Check at 1-2 weeks after each dose increment, at 3 months, then every 6 months 2:

• Blood pressure (watch for hypotension)
• Renal function (creatinine, eGFR)
• Electrolytes (potassium, sodium)

When to Stop or Adjust

• Stop ACE-I if renal function deteriorates substantially 2
• Avoid triple RAAS blockade (ACE-I + ARB + MRA) due to increased risk of renal dysfunction and hyperkalemia 1
• Never use diltiazem or verapamil in HFrEF—they increase HF worsening and hospitalization (Class III) 1

Common Pitfalls to Avoid

1. Delaying beta-blocker initiation: Start once patient is stable on ACE-I, not months later—beta-blockers reduce sudden death 10

2. Using diuretics alone long-term: This activates neurohormonal systems (renin, angiotensin II, aldosterone, norepinephrine) and worsens outcomes 4

3. Inadequate uptitration: Aim for target doses proven in trials, not just symptom relief 2

4. Prescribing NSAIDs: These worsen HF and should be strictly avoided 2

5. Forgetting SGLT2i: This is now part of foundational quadruple therapy, not an "add-on" 5, 6, 3

6. Not continuing GDMT in improved LVEF: Patients with previous HFrEF who now have LVEF >40% should continue their HFrEF treatment 5, 3